News & Events about Evolus Inc.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference. Event: SVB Securities Global Biopharma...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today presented interim data from its Phase II clinical study evaluating an 'extra-strength' formulation for extended duration of Jeuveau...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva (prabotulinumtoxinA), a neurotoxin...
Evolus (NASDAQ:EOLS Get Rating) had its target price hoisted by SVB Leerink from $18.00 to $20.00 in a research note published on Thursday morning, Benzinga reports. They currently have an outperform rating on the stock. A number of other brokerages also recently weighed in on EOLS. Mizuho ...
Evolus (NASDAQ:EOLS Get Rating) had its price target hoisted by Mizuho from $15.00 to $17.00 in a research report report published on Thursday, The Fly reports. They currently have a buy rating on the stock. Separately, HC Wainwright restated a buy rating on shares of Evolus in a report on Wednesday...